OncoPro KRAS Rapid Test: Advanced Cancer Mutation Detection
Comprehensive Introduction to KRAS Mutation Testing
The OncoPro KRAS Rapid Test represents a breakthrough in personalized cancer medicine, offering healthcare providers and patients critical genetic information to guide treatment decisions. KRAS mutations are among the most common genetic alterations found in various cancers, particularly colorectal, lung, and pancreatic malignancies. Understanding your KRAS status can significantly impact your treatment journey and overall outcomes.
This advanced molecular diagnostic test utilizes cutting-edge Real-Time PCR technology to detect specific KRAS gene mutations with exceptional accuracy and speed. By analyzing tumor tissue samples, the test provides oncologists with essential information about whether targeted therapies will be effective for your specific cancer type. The rapid turnaround time—next working day results—ensures that treatment decisions can be made promptly, reducing anxiety and accelerating your path to appropriate care.
What the OncoPro KRAS Rapid Test Detects
The OncoPro KRAS Rapid Test specifically identifies mutations in the KRAS gene, which plays a crucial role in cell signaling pathways that control cell growth and division. When mutated, the KRAS gene can drive uncontrolled cancer cell proliferation and resistance to certain targeted therapies.
Key Mutations Detected:
- KRAS G12 mutations (including G12D, G12V, G12C)
- KRAS G13 mutations
- Other clinically relevant KRAS codon 12 and 13 mutations
- Multiple mutation variants that affect treatment response
These specific mutations are critical because they can determine whether patients will respond to EGFR inhibitor therapies, which are commonly used in treating colorectal cancer and other malignancies.
Who Should Consider the OncoPro KRAS Rapid Test
This test is particularly important for patients diagnosed with specific cancer types where KRAS mutation status directly influences treatment options.
Primary Candidates Include:
- Patients newly diagnosed with colorectal cancer
- Individuals with advanced or metastatic colorectal cancer
- Patients with non-small cell lung cancer (NSCLC)
- Those diagnosed with pancreatic cancer
- Patients considering EGFR inhibitor therapy
- Individuals whose previous treatments have shown limited effectiveness
- Patients seeking personalized treatment approaches
Symptoms and Clinical Scenarios:
- Recent colorectal cancer diagnosis with planned treatment initiation
- Progression of existing cancer despite current therapy
- Planning for targeted therapy options
- Metastatic cancer requiring treatment optimization
Significant Benefits of KRAS Mutation Testing
Understanding your KRAS mutation status provides numerous advantages in your cancer treatment journey, enabling more informed decisions and potentially better outcomes.
Key Benefits:
- Personalized Treatment Planning: Guides oncologists in selecting the most appropriate targeted therapies
- Avoidance of Ineffective Treatments: Prevents use of expensive medications that won’t work for KRAS-mutated cancers
- Improved Treatment Outcomes: Increases likelihood of successful therapy by matching treatment to genetic profile
- Cost-Effective Care: Reduces healthcare costs by avoiding ineffective treatments
- Rapid Results: Next-day reporting enables quick treatment decisions
- Comprehensive Analysis: Detects multiple KRAS mutation variants in a single test
- High Accuracy: Real-Time PCR technology ensures reliable, reproducible results
Understanding Your Test Results
Interpreting your OncoPro KRAS Rapid Test results is straightforward, but should always be discussed with your healthcare provider in the context of your overall clinical situation.
Possible Results and Their Meanings:
- KRAS Mutation Detected: Indicates the presence of specific KRAS mutations that may make certain targeted therapies less effective. Your oncologist will consider alternative treatment options.
- No KRAS Mutation Detected: Suggests that EGFR inhibitor therapies may be appropriate and potentially effective for your cancer treatment.
- Insufficient Sample: Rare cases where the tissue sample doesn’t contain enough tumor cells (less than 10%) for accurate analysis, requiring additional sampling.
Your healthcare provider will explain how these results impact your specific treatment plan and discuss the next steps in your care journey.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| OncoPro KRAS Rapid Test | $438 USD | $488 USD |
Sample Requirements and Processing:
- Sample Type: Formalin fixed paraffin embedded (FFPE) tissue block
- Minimum Tumor Content: At least 10% tumor tissue required
- Shipping: Room temperature shipment
- Turnaround Time: Samples accepted daily by 11 am; Reports delivered next working day
Nationwide Availability and Booking
We have diagnostic branches conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more cities nationwide.
Our experienced molecular diagnostics team is ready to assist you with the OncoPro KRAS Rapid Test and provide the critical genetic information needed for your cancer treatment decisions.
Take Action Today
Don’t leave your treatment decisions to chance. The OncoPro KRAS Rapid Test provides essential genetic information that can significantly impact your cancer treatment success. Contact us now to schedule your test and take the first step toward personalized cancer care.
Call or WhatsApp: +1(267) 388-9828
Our genetic counseling team is available to answer your questions and help you understand how KRAS testing can benefit your specific situation. Book your OncoPro KRAS Rapid Test today and empower yourself with the knowledge needed for informed treatment decisions.
